{"id":3144,"date":"2026-07-11T03:16:07","date_gmt":"2026-07-11T03:16:07","guid":{"rendered":"https:\/\/www.thefullerene.com\/?p=3144"},"modified":"2026-07-14T11:24:01","modified_gmt":"2026-07-14T11:24:01","slug":"fullerene-radiation-dermatitis-research","status":"publish","type":"post","link":"https:\/\/www.thefullerene.com\/zh\/fullerene-radiation-dermatitis-research\/","title":{"rendered":"\u5bcc\u52d2\u70ef\u5728\u653e\u5c04\u6027\u76ae\u708e\u7814\u7a76\u4e2d\u7684\u5e94\u7528\uff1a\u8bc1\u636e\u3001\u914d\u65b9\u4e0e\u5b89\u5168\u8fb9\u754c"},"content":{"rendered":"\n

Research into fullerene in radiation dermatitis<\/strong> has moved beyond laboratory theory. Preclinical studies have investigated hydroxylated fullerenes, or fullerenols, in irradiated cells and animal skin, while randomized clinical studies published in 2025 and 2026 evaluated fullerene-containing topical creams in patients receiving radiotherapy.<\/p>\n\n\n\n

The results are promising. In the reported studies, fullerene-containing formulations were associated with lower grades or incidence of acute radiation dermatitis, delayed onset of skin reactions, reduced pain, or shorter duration of clinically significant dermatitis.<\/p>\n\n\n\n

However, these findings do not establish that raw Fullerene C60, every fullerene derivative, or every commercial fullerene cream is safe and effective for irradiated skin. The evidence applies to specific finished formulations, dosing schedules, patient populations, comparators, and study protocols.<\/p>\n\n\n\n

The central scientific question is therefore not simply whether fullerene can scavenge reactive species. It is whether a precisely characterized fullerene material can be formulated into a stable, tolerable, clinically evaluated topical product without creating additional risks for irradiated or barrier-damaged skin.<\/p>\n\n\n\n

This article reviews the current evidence, distinguishes pristine C60 from fullerenol and finished creams, examines the most important formulation variables, and defines the boundaries that researchers, formulators, suppliers, and patients should not cross.<\/p>\n\n\n\n

Medical notice:<\/strong> This article is for scientific, formulation, and procurement reference only. It does not provide medical advice or recommend self-treatment. Patients receiving radiotherapy should follow the skin-care protocol provided by their radiation oncology team.<\/p>\n\n\n\n

What Is Radiation Dermatitis?<\/h2>\n\n\n\n

Radiation dermatitis is a skin reaction caused by ionizing radiation delivered during radiotherapy. Acute radiation dermatitis can develop during treatment or shortly afterward and may present as erythema, dryness, itching, discomfort, peeling, pain, or moist desquamation. Severity depends on radiation dose, fractionation, treatment location, concurrent therapy, patient characteristics, skin folds, friction, and other clinical factors.<\/p>\n\n\n\n

Ionizing radiation can damage skin through direct interactions with cellular DNA and through indirect processes involving reactive oxygen species. Repeated exposure during fractionated radiotherapy can affect basal keratinocytes, inflammatory signaling, vascular structures, hair follicles, and the skin barrier.[1]<\/a><\/sup><\/p>\n\n\n\n

Current supportive-care strategies may include gentle washing, moisturization, topical corticosteroids, barrier films, dressings, and other interventions selected according to treatment site, dermatitis grade, institutional protocol, and clinician assessment.[2]<\/a><\/sup><\/p>\n\n\n\n

No single intervention is appropriate for every patient or every stage of radiation dermatitis. This is the clinical context in which fullerene-containing formulations are being investigated.<\/p>\n\n\n\n

Why Are Fullerenes Being Studied?<\/h2>\n\n\n\n

The scientific rationale centers on oxidative stress. The conjugated carbon cage of fullerene materials can participate in electron-transfer and radical-related reactions. Hydroxylated fullerene derivatives have been investigated as scavengers of reactive oxygen and nitrogen species in laboratory systems.<\/p>\n\n\n\n

Fullerenols are particularly relevant because hydroxyl groups attached to the fullerene cage can improve water compatibility compared with pristine C60. This allows researchers to prepare aqueous or emulsion-based systems that are more practical for biological testing.<\/p>\n\n\n\n

In cell and animal studies, fullerenol preparations have been reported to reduce intracellular reactive oxygen species, DNA damage, apoptosis, epidermal thickening, collagen deposition, and damage to skin appendages after irradiation.[3]<\/a><\/sup>[4]<\/a><\/sup><\/p>\n\n\n\n

These findings provide a plausible mechanism for further research. They do not prove that every topical fullerene formulation will produce the same effect in patients.<\/p>\n\n\n\n

A molecule\u2019s radical-scavenging activity in a laboratory assay is only one part of product performance. Clinical results also depend on delivery to the relevant skin layer, concentration, retention time, formulation vehicle, stability, tolerability, radiation schedule, patient adherence, and the condition of the skin barrier.<\/p>\n\n\n\n

\u201cFullerene\u201d Is Not One Interchangeable Material<\/h2>\n\n\n\n

One of the most important safety and interpretation issues is terminology. Research papers and commercial pages may use \u201cfullerene\u201d to describe substantially different materials.<\/p>\n\n\n\n

Material Type<\/th>Basic Description<\/th>Formulation Relevance<\/th><\/tr><\/thead>
Pristine Fullerene C60<\/td>Unmodified carbon cage composed of 60 carbon atoms<\/td>Water-insoluble and requires an appropriate solvent, dispersion, carrier, or processing method<\/td><\/tr>
Fullerene C70<\/td>Elongated carbon cage composed of 70 carbon atoms<\/td>Different molecular, optical, and formulation properties from C60<\/td><\/tr>
Fullerenol<\/td>Hydroxylated fullerene carrying multiple hydroxyl groups<\/td>Typically more water-compatible and widely used in radioprotection studies<\/td><\/tr>
Encapsulated or carrier-bound fullerene<\/td>Fullerene incorporated into lipids, polymers, surfactants, or other carrier systems<\/td>Carrier composition may control stability, penetration, and tolerability<\/td><\/tr>
Finished fullerene cream<\/td>Multicomponent topical formulation containing fullerene-related material and excipients<\/td>Clinical evidence applies to the complete tested product, not the fullerene ingredient in isolation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Evidence from a hydroxylated fullerenol cannot automatically be applied to pristine C60 powder. Evidence from one finished cream cannot automatically be applied to another cream with different fullerene chemistry, concentration, emulsifiers, humectants, preservatives, or penetration enhancers.<\/p>\n\n\n\n

\"Pristine
Pristine C60 fullerenol carrier dispersion and finished topical formulation comparison<\/figcaption><\/figure>\n\n\n\n

This distinction should be maintained throughout scientific publications, marketing materials, procurement discussions, and regulatory submissions.<\/p>\n\n\n\n

Current Evidence at a Glance<\/h2>\n\n\n\n
Evidence Stage<\/th>Study<\/th>Main Finding<\/th>Important Limitation<\/th><\/tr><\/thead>
Cell and material research<\/td>Zhao et al., 2021<\/td>Scalable fullerenol material showed radical-scavenging and skin-radioprotection potential in experimental systems<\/td>Preclinical evidence does not establish clinical efficacy<\/td><\/tr>
Cell and mouse study<\/td>Yin et al., 2023<\/td>Topical fullerenol reduced several signs of radiation-induced skin injury in mice<\/td>Animal skin and human radiotherapy are not equivalent<\/td><\/tr>
Randomized breast cancer study<\/td>Wang et al., 2025<\/td>Fullerene cream was associated with lower ARD grades, delayed onset, less pain, and better reported quality of life<\/td>Small, single-center, nonblinded study; 81 patients included in final analysis<\/td><\/tr>
Phase II head and neck cancer trial<\/td>Liu et al., 2026<\/td>Fullerene cream reduced grade 2 or higher and grade 3 or higher ARD compared with trolamine<\/td>Single-center and product-specific; broader replication and long-term evidence remain necessary<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\"\"
Pristine C60 fullerenol carrier dispersion and finished topical formulation comparison<\/figcaption><\/figure>\n\n\n\n

What the Preclinical Evidence Shows<\/h2>\n\n\n\n

A 2021 study described a scalable route for producing fullerenols with free-radical-scavenging activity and investigated their potential for skin radioprotection.[3]<\/a><\/sup><\/p>\n\n\n\n

A subsequent 2023 study evaluated topically applied fullerenols in irradiated keratinocytes, fibroblasts, and a mouse model of radiation dermatitis. The researchers reported reduced intracellular reactive oxygen species, less DNA damage and apoptosis in cell models, and improvements in several skin-injury indicators in mice.[4]<\/a><\/sup><\/p>\n\n\n\n

The mouse study also reported reduced epidermal thickening, collagen deposition, and skin-appendage damage. These results support the biological plausibility of topical fullerenol research.<\/p>\n\n\n\n

Nevertheless, preclinical findings have several boundaries:<\/p>\n\n\n\n